BC Extra | Sep 6, 2019
Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

Sumitomo Dainippon will pay $3 billion to acquire Roivant's stakes’ in five of its “vants” encompassing women's health, urology and rare diseases, propping up its pipeline as it anticipates losing U.S. market exclusivity on antipsychotic...
BC Extra | Jul 3, 2019
Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

Otilimab triggers milestone for MorphoSys MorphoSys AG (Xetra:MOR; NASDAQ:MOR) will receive a milestone payment of €22 million ($27.7 million) after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) started the Phase III ContRAst program of otilimab to treat...
BC Week In Review | Jun 1, 2018
Clinical News

Boston Biomedical reports detailed data from Phase III gastric cancer trial of napabucasin

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from the Phase III BRIGHTER trial in 714 patients with previously treated advanced gastric or gastroesophageal junction cancer showing that second-line...
BC Week In Review | Jul 7, 2017
Clinical News

Sumitomo's napabucasin unlikely to meet Phase III gastric cancer endpoint

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said an interim analysis by a DSMB showed that napabucasin (BBI608, BB608) was unlikely to meet the primary endpoint of improving overall survival...
BC Week In Review | Jul 6, 2017
Clinical News

Boston Biomedical reports Phase Ib/II data for napabucasin in various cancers

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from various patient populations in a Phase Ib/II trial evaluating twice-daily oral napabucasin (BBI608, BB608) plus paclitaxel to treat advanced malignancies....
BC Week In Review | Jun 30, 2017
Clinical News

Boston Biomedical reports Phase Ib/II data for Nexavar combos in HCC

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from 14 patients with hepatocellular carcinoma (HCC) in the Phase Ib/II BBI608-503-103HCC trial showing that twice-daily 160 or 240 mg oral...
BC Extra | Jun 26, 2017
Clinical News

Sumitomo's napabucasin unlikely to meet gastric cancer endpoint

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said an interim analysis by a DSMB showed napabucasin (BBI608) was unlikely to meet the primary endpoint in the Phase III BRIGHTER trial...
BC Innovations | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
BC Week In Review | Oct 17, 2016
Clinical News

Napabucasin: Phase III final data

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan   Product: Napabucasin ( BB608 , BBI608 )   Business: Cancer   Molecular target: Signal transducer and activator of transcription 3 (STAT3)   Description: Small molecule targeting cancer stem cells...
BC Week In Review | May 30, 2016
Clinical News

Napabucasin: Additional Phase Ib/II data

Data from a cohort of 27 patients with non-small cell lung cancer (NSCLC) in the open-label, North American Phase Ib/II BBI608-201 trial showed that twice-daily oral napabucasin, starting at a dose of 240 mg, plus...
Items per page:
1 - 10 of 28